HealthNews
Gilead Faces Price Debate Over ‘Miracle’ HIV Drug Lenacapavir
For the first time in the four-decade fight against HIV, there is a “miracle” drug that can all but eliminate the risk of infection, but in the Latin American countries where it was tested, most people can’t afford it.
Trials show that lenacapavir, made by Gilead Sciences, is almost 100% effective in preventing HIV infection. With just two shots a year, those taking it will avoid contracting the virus even when frequently exposed.
The drug, which many believe could bring an end to the global HIV pandemic, costs $14,000 a dose in the United States. Gilead has agreed to license generic versions of the pre-exposure prophylaxis (PrEP) medication at around $40 a dose in 120 low- and middle-income countries, but many Latin American countries are being quoted a higher price.
Brazil, Mexico, Argentina, and Peru are among those with serious HIV epidemics that do not qualify for the reduced price, despite having run some of the clinical trials that proved the drug works.
Their status as “upper-middle income countries” means they are too rich to qualify for the cut-price generic version, and yet they remain too poor to pay the US price.
Anger over the impasse spilled onto the stage at the opening ceremony of the International AIDS Society Conference in Rio De Janeiro this week.
Activists waved posters and chanted protests — “Pharma greed is killing us!” “Pills cost lives!” “Latin America for the cure!” — to applause and cheers from the audience.
Brazilian officials backed them.
Dr. Alexandre Padilha, the country’s health minister, told the room that negotiations with Gilead had stalled because the pharma giant wanted a price 10 times higher than that being paid by Indonesia and Thailand — both, like Brazil, upper-middle-income countries.
“Innovation without access is not an innovation,” he said. “It is an injustice.”
Gilead says it’s negotiating with regional Latin American governments directly, but hasn’t said what price it is asking, or indicated when a deal might land.
Winnie Byanyima, Executive Director of UNAIDS, said Brazil had spent more than a year trying to strike a deal with Gilead, without success.
Brazil “should not now be forced to stand in the back of the queue,” she added.
Some suspect Gilead is holding out because Brazil has a law that obliges the state to provide treatment, no matter the cost, if it’s needed.
Draurio Barreira, head of AIDS and TB at Brazil’s health ministry, told The Telegraph that this constitutional guarantee may be working against it in price negotiations. The Telegraph, like Business Insider, is part of the Axel Springer Global Network.
Because the government is legally obliged to provide treatment, manufacturers calculate that Brazil cannot walk away from a deal and price accordingly, he said.
“They want the full price because the law will oblige the government to buy,” he added, though he made clear that this was his own view, rather than something Gilead had confirmed.
However, a spokesperson for Gilead said they did not “agree with that characterization,” adding: “Consistent with our approach globally, Gilead follows the regulatory, pricing, and reimbursement processes established within Brazil’s healthcare system and will continue working collaboratively with governments, communities, and regional partners to help bring this innovation to the people and communities that stand to benefit most from it.”
Frustration over the speed of the rollout of lenacapavir has dominated the Rio conference and threatens to damage Gilead’s reputation.
This is despite the company doing more in the area of HIV to innovate new drugs and make them available in volume than any other major company over the course of the AIDS pandemic.
Gilead told The Telegraph it understood the “urgency” of expanding access to lenacapavir in Latin America and the Caribbean, adding that it already covers 24 countries in the region.
It was in talks with Brazil but was prioritising countries with the “greatest HIV burden and even more limited financing capacity”, said a spokesman.
Innovation in the same category of long-lasting PrEP drugs from other companies might ultimately force prices down.
On Tuesday, Fiocruz, Latin America’s largest biomedical research and public health institution, tied to Brazil’s ministry of health, signed a memorandum of understanding with MSD Brasil, Merck’s local arm, to explore manufacturing alimatravir, a once-monthly oral pill in the same new generation of HIV prevention drugs.
The drug is still in Phase 3 trials but potentially gives Brazil a route around the pricing standoff with Gilead if the trials are successful.
The same day, it was announced that Brazil would incorporate ViiV healthcare’s long-acting cabotegravir — a British-developed HIV prevention drug injected every two months — into its PrEP program through SUS, Brazil’s Unified Health System, by the end of the year as the company had offered “an acceptable price,” said Dr. Padilha.
It will depend on a final agreement and review by Conitec, the advisory body for the country’s health system.
Long-acting PrEP products offer the single biggest opportunity to control the HIV virus that has evaded a vaccine for decades, experts say.
They are easy to administer and track, and for people at high risk of infection, they remove the stigma of having to take a daily pill.
Brazil is home to roughly 1 million people living with HIV, nearly 45% of all HIV cases in Latin America.
Although the region’s largest economy, it has just 6,000 people on long-acting PrEP out of 233,000 total PrEP users nationally, with the vast majority still reliant on daily pills.
Latin America is also one of the few regions of the world where the HIV epidemic is moving in the wrong direction.
UNAIDS data shows new infections in the region have climbed 25% since 2010, even as Sub-Saharan Africa cut infections by 62% over the same period.
Supply, not just price, is the other major constraint, as the drug was only first licensed in its twice-yearly form in 2025, and manufacturing capacity is still building.
Even in countries covered by Gilead’s discounted license, doses remain scarce, with fewer than 250,000 people across the developing world now accessing the product.
Byanyima of UNAIDs wants that scaled up to 20 million within three years — a target she argues is well within reach, pointing out that the world managed to vaccinate 4.5 billion people against COVID-19 in a single year.
“This is not beyond the world’s capacity,” she said. “So I ask my friends at Gilead again, help us to change this.”
Gilead is famously a volume producer of HIV and other important developing world drugs and is likely to welcome the challenge.
“Access discussions extend beyond pricing alone and involve regulatory pathways, implementation readiness, procurement mechanisms, and long-term sustainability,” it told the Telegraph.
“Gilead remains committed to working collaboratively with stakeholders across the region to expand access to lenacapavir for HIV prevention.”
HealthNews
Birth order may predict risk for allergies, psychiatric disorders and substance use
You can now hear Fox News stories!
According to a new, massive study, the age of a sibling can affect health later in life.
Researchers from Columbia University and the University of Chicago analyzed medical data collected from 10,000,000 U.S. sibling siblings for two decades. They found that there may be a link between birth order and specific health risks.
Researchers examined 569 categories of disease across families, and found 150 that had a significant relationship with the birth order.
LONGER LIFE, BAD HEALTH? Scientists Discover a Troublesome Trend Across Generations
The first-born child showed an increased likelihood of receiving neurodevelopmental or psychiatric diagnosis, such as autism, ADHD and Tourette’s syndrome, and immune-allergic disorders like food allergies.
Statistics show that second-borns are more likely to suffer from migraines, shingles and substance abuse disorders. They also have a higher risk of gastrointestinal problems like gastritis.
While discussing the results on Fox & Friends, Dr. Marc Siegel (senior medical analyst at Fox News) noted the importance of such a large-scale research.
The doctor stated, “I like this study as it raises more questions than answers. But I do think I know some of the answers.”
CLICK HERE TO READ MORE HEALTH STORIES
Siegel’s own theory about parenting behavior was offered in response to the increased prevalence of ADHD with first-borns.
My theory is that they are getting more stimulation. He said that the parents hover over their children, like helicopters. “They don’t even know what to do,” he added.
Test Yourself with Our Latest Lifestyle Quiz
Siegel, in addressing the disparity between allergic conditions and the early exposure to the environment, said, “I believe it is because the immune system of the firstborn has not seen the environmental before.” If it is not properly set, then you will get an allergic reaction.
Siegel also discussed biological and psychological aspects when evaluating the differences between sibling.
I think that the womb is different after the first pregnancy, so the second baby will have a used womb. He said that the womb is more prepared for it because it has already been used.
CLICK HERE FOR OUR HEALTH NEWSLETTER
Siegel, in a response to the increased rate of substance abuse disorders among children born second, suggested that emotional factors may also be at play. “It could all come down to the same thing: I want attention. I’m looking for attention. “I want to do something that will make you laugh.
The study has some limitations, even though it highlights trends across a wide population.
These findings show correlations, not direct causality, which means that the trends aren’t always due to physiological changes, early microbe exposures, or social dynamics.
The data also relies heavily on the commercial health insurance claims which may reflect different diagnoses, differences in healthcare seeking behavior, and parental attention, rather than just true biological functions.
CLICK HERE TO DOWNLOAD FOX NEWS APP
These associations are also complicated by factors such as age differences between parents and siblings. Researchers concluded that birth order is a risk indicator at the population level, rather than an accurate health predictor.
Nature Health published the research.
HealthNews
West Nile Virus found in one-third of mosquitos sampled within Salt Lake City district
County health officials report that West Nile Virus has been detected in 35 percent of mosquitoes screened this week at the Salt Lake City Mosquito Abatement District. This represents a risk “significantly greater than normal” for the virus.
Salt Lake County Health Department officials announced on Wednesday that a second case of West Nile virus was also reported. On July 30, the county reported its first case of West Nile virus of the year.
West Nile Virus, the virus most commonly spread by mosquitoes and which has a wide range of effects on humans.
According to the Centers for Disease Control and Prevention, some people will not show symptoms. However, they can develop headaches, body aches, and fever within two to fourteen days. The severe cases may result in high temperatures, stiff necks, confusion, muscle convulsions or even death.
Salt Lake County Health Department advises people to:
HealthNews
Bat tests positive for rabies after getting caught in Olympic National Park hiker’s hair
The rabies test results for the bat, which swooped and caught a woman in her hair near Staircase Bridge at Olympic National Park have been confirmed. Health officials are urging the woman to get medical treatment and any other person who has had contact with this animal.
A rabid swarming bat was discovered Sunday, near Staircase Bridge. Olympic National Park issued a warning on Wednesday that the bat was briefly caught in the hair of an unidentified female at about 2 pm.
Mason County Health Department, 360-427-9700, Ext. 405.
Health officials said that the bat also attacked other people in the vicinity, but it was not known if anyone else came into contact with the bat.
If you have been in contact with bats, but were not bitten by one, contact your local health department and a doctor to see if treatment is needed.
If you are concerned about a pet’s direct contact with bats, contact your veterinarian.
The rabies virus is deadly and can infect any mammal. Bats are the main carriers. The virus can be transmitted by the saliva of infected animals or their bites or scratches.
Small bites or scratches from bats may be inconspicuous and not painful. If you believe that you may have come into contact with a Bat, it is important to immediately consult a healthcare provider in order to assess the risks of exposure.
When medical attention is sought promptly following exposure, rabies can be avoided.
According to park officials, Washington has a large number of bats that are in good health.
According to park officials, bats have an important role in the ecosystem. This includes pest control, pollination and seed dispersal.
The Olympic National Park does not allow visitors to touch, handle or feed bats. If you see a dead bat or if it is alive, keep your distance. Notify the park staff.
HealthNews
Student, 19, Dies After Taking Drug Used by Millions of Americans
According to reports, the Californian teenager was found lying on her bathroom floor.
The 19-year old college student who died was found to have taken a popular GLP-1 drug for weight loss.
Josephine Nasr died on September 23, 2025, in the dorm of her London college after she took tirzepatide.
Under the brand names Mounjaro or Zepbound, this popular drug belongs to a class of drugs called GLP-1/GIP receptor-agonists.
Gallup’s National Health and Wellness Index shows that 15 percent of Americans take a weight-loss medication. This includes “semaglutide, (brand names Ozempic, Wegovy, and liraglutide, (brand name Saxenda) or tirzepatide, (brand names Mounjaro, Zepbound, and Mounjaro).
According to The Times of London (which reported Nasr began taking Zepbound in summer 2025), Nasr received Zepbound from a U.S. physician. Nasr wasn’t obese but her BMI was classified as “overweight.”
Nasr told her family that she felt nauseous and was vomiting the night before her death. She was enrolled in her second-year of legal and international studies at East London University and was planning to graduate by 2027.
According to Cleveland Clinic, GLP-1s can cause nausea or vomiting.
Anastasia Nasr was worried about her sister’s dehydration, and so ordered Nasr IV fluids. After she couldn’t reach her by phone, Anastasia Nasr contacted the security team at the college.
Nasr was found on the bathroom floor by the team when they entered Nasr’s room. It was around two hours since Nasr last spoke to her family on the telephone.
The Times reported that next to her, there was an empty GLP-1 vial.
Nasr died on the spot after an ambulance arrived.
On August 3, an inquest was conducted at the East London Coroner’s Court regarding Nasr’s demise. The coroner Graeme Irvine determined that cardiac arrhythmia was the cause of her death.
In his postmortem, pathologist Alan Bates determined that Nasr suffered from a condition of the heart known as myocardial bridge. The coronary artery usually runs above a heart muscle, but in this case, the artery passes through the muscle.
The condition is not harmful to health but can lead to chest pain. It is estimated that between 16 to 30 percent of all people were born with the condition.
Bates stated that vomiting caused by tirzepatide may have led to low blood sugar and an electrolyte balance that might have resulted in arrhythmia. Nasr, he said, was an “otherwise healthy young woman”, but her heart condition could have contributed negatively to the outcome.
Lorin Mansour – Nasr’s mom – reportedly fainted upon hearing the news.
She was always happy and put others first. George Nasr said that Nasr loved to travel and enjoy the ocean.
Mansour said, “Josephine’s willingness to assist others showed her commitment to the Coptic faith.”
Get a full year’s access to The Looker & The Daily Beast at just $35.
Every Month
$1
The first month is $5.99/month
Access to unlimited content (web and app)
Newsletters with no ads exclusives
Access to comments
Crosswords for daily use
Launches & Events Sneak Peek
Automatic renewal at $5.99 per month. Cancel at any time
Get the Best Price
Yearly
$35
The first year is $59.99/year
Annual rate discounted – save 47%
Access to unlimited content (web and app)
Newsletters with no ads exclusives
Access to comments
Crosswords for daily use
Launches & Events Sneak Peek
Automatic renewal at $59.99 per year. Cancel at any time
Ad-Free
$79
The first year is $119.99/year
Annual Discount
Enjoy premium reading without ads
Access to unlimited content (web and app)
Newsletters with no ads exclusive to subscribers
Access to comments
Crosswords for daily use
Launches & Events Sneak Peek
Automatic renewal at $119.99 per year. Cancel at any time
You already have an active subscription.
All set?
Thank you for your subscription.
HealthNews
As measles outbreaks grow in the U.S., maps and charts show a record number of cases
Centers for Disease Control and Prevention (CDCP) data show that the United States has seen the highest number of measles outbreaks in the past three decades, as the disease spread across multiple states.
Mid-July saw the total surpass 2025 which was the worst year of recent times with over 2,200 cases confirmed. The U.S. is at risk of losing the official status it holds since 2000, that has been attributed to them for eliminating measles.
The measles virus is highly contagious. It can sometimes cause serious infections of the brain and lungs that may lead to deafness, cognitive problems, or even death. Vaccination is a safe, highly effective and medically proven way to prevent it.
CBS News’ data team tracked measles confirmed cases across the country as state health departments released new data.
More than 750 of the 2,289 cases confirmed last year were linked to an outbreak that occurred in West Texas and led to two deaths.
Before 2025, prior to 2019, the most recent year with the largest number of confirmed cases was 2019. This was driven by outbreaks occurring in New York State, California, and Washington. The total number of cases was usually much lower.
Experts in health care point out that the increase of infectious diseases such as measles is primarily due to decreased vaccination rates. Most cases are in unvaccinated people, and the outbreaks spread to communities that have lower vaccination rates.
CDC data show that approximately 93% of U.S. kindergarteners were vaccinated for measles in 2021-2022 and only 92.7% during 2023-2024. It is down from the 95.2% in the school year 2019-2020 — an important threshold for keeping people safe. This threshold was only reached by 10 states.
The CDC says that “when more than 95 percent of the people living in a given community have been vaccinated,” they are most likely to be protected by herd immunity.
On “Face the Nation With Margaret Brennan”, Dr. Jay Bhattacharya of the National Institutes of Health said, “I believe that it is very important for parents to vaccinate children, particularly for the measles, the DTP and all the childhood standard vaccines.”
-
Business2 weeks agoMinnesota bans crypto ATMs after elderly population was targeted
-
Business5 days agoElon Musk plans 100 million-square-foot terafab semiconductor plant near Houston
-
Business3 days agoVandalized fiber lines cause Verizon service outage for thousands of SoCal customers
-
Entertainment2 weeks agoBrand New Day’ Post Credits Scene, Explained
-
Business1 week ago
Why extreme heat can force airlines to leave passengers behind
-
Business5 days agoHealth department investigating after seeing more than 5x increase in cyclosporiasis cases in McHenry County
-
BBC News World1 week agoSee the Sun like never before with most detailed images yet
-
BBC News World1 week agoHuman remains exhumed at site of controversial World War II massacres in Ukraine: “Each of them had their dreams”
